(CercleFinance.com) – Novo Nordisk announces the termination of the FLOW trial, evaluating the effects of its once-a-week injectable semaglutide versus placebo on the progression of renal failure in patients with type 2 diabetes or chronic kidney disease.
This decision was based on a recommendation from the independent data monitoring committee, concluding that the results of an interim analysis met certain predefined criteria to stop the trial prematurely for reasons of effectiveness.
Based on this, the trial closure process will be initiated. To protect the integrity of the trial, Novo Nordisk will remain blind to its results until completion. He expects FLOW results to be released in the first half of 2024.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
This is a Smartvoice article: see legal notices